Neladenoson bialanate - Bayer HealthCare Pharmaceuticals

Drug Profile

Neladenoson bialanate - Bayer HealthCare Pharmaceuticals

Alternative Names: BAY 1067197

Latest Information Update: 13 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Heart failure therapies; Nitriles; Pyridines; Pyrrolidines; Thiazoles
  • Mechanism of Action Adenosine A1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic heart failure

Most Recent Events

  • 20 Jun 2018 Bayer completes a phase II trial in Chronic heart failure in USA, Austria, Germany, Bulgaria, Spain, Portugal, Greece, Belgium, Israel, Italy, Japan and Poland (PO) (NCT03098979)
  • 16 May 2018 Bayer completes a phase II trial in Chronic heart failure in Spain, Bulgaria, Germany, USA, Belgium, Greece, Italy, Netherlands, Israel, Japan and Poland (PO) (NCT02992288)
  • 10 May 2017 Phase-II clinical trials in Chronic heart failure in Austria (PO) (NCT03098979)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top